Abstract 5205
Background
Our purpose was to study parameters of the cellular immunity in patients with different stages of colorectal cancer with and without circulating tumor cells (CTCs).
Methods
The presence of CTCs and parameters of the cellular immunity were studied in 60 colorectal cancer (CRC) patients: stage II – 20, stage III – 12, stage IV – 28 patients, adenocarcinoma in all cases. Blood levels of CTCs were determined before the treatment using the CellSearch System (Janssen Diagnostics, LLC) with iron microparticles coated with antibodies to epithelial cell adhesion markers EpCAM, CD45 and cytokeratins 8,18,19. Subpopulations of lymphocytes were studied using the FACSCantoII flow cytometer (BD): percentage of T-B-NК-cells, Tregs; activated CD4+ and CD8+ cells, naive T-lymphocytes and memory T cells; expression of CD335, perforin and granzyme B was evaluated in NК cells.
Results
The results revealed a number of differences in immunological parameters in patients with and without CTCs. Stage II CRC with CTCs showed statistically significantly higher content of lymphocytes (19.1±2.7 vs 15.6±1.4%), CD335+ NK cells (44.9±7.6 vs 19.2±4.0%) and the respiratory burst index in granulocytes (97.5±1.6 vs 92.3±1.2%); p < 0.05 in all cases. Stage III CRC with CTCs was characterized by decreased lymphocyte and monocyte levels, while granulocyte content increased. These patients demonstrated elevated levels of CD4+ cells with early and late activation markers: CD38+ and HLA-DR+ by 2 times, CD25+ by 6 times, p < 0.05 in all cases. CTC-positive patients with stage IV CRC, compared to CTC-negative ones, showed lower levels of NK cells (16.6±2.0 vs 28.4±5.5%), CD4+CD69 + (5.1±0.8 vs 8.2±1.0%), and CD8+CD25 + (2.8±0.48 vs 5.5±1.1%; p < 0.05).
Conclusions
CTCs in locally advanced CRC is associated with stimulation of functional parameters of innate immunity and activated Th, while in metastatic CRC - with inhibition of cytotoxic lymphocytes of innate and adaptive immunity, which, apparently, is associated with poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5658 - Detection of 5-hydroxymethylcytosine in Circulating-Free DNA for Early Diagnosis of Colorectal Cancer
Presenter: Tianyu Liu
Session: Poster Display session 2
Resources:
Abstract
5779 - Detection of 5-hydroxymethylcytosine in Circulating-Free DNA for Prediction of The Efficacy of Conversion Therapy for Colorectal Cancer Liver Metastases
Presenter: Wenju Chang
Session: Poster Display session 2
Resources:
Abstract
4672 - mCRC gene profiling using the Idylla platform
Presenter: Christopher Bricogne
Session: Poster Display session 2
Resources:
Abstract
3393 - PIK3CA mutation in metastatic colorectal cancer (mCRC): association with clinico-pathological features and outcome
Presenter: Valentina Fanotto
Session: Poster Display session 2
Resources:
Abstract
1317 - Patient-Derived Xenografts (PDX) Identifies JMJD6 Inhibitor as an Effective Therapeutic Medicine in Colorectal Cancer.
Presenter: Feng Ye
Session: Poster Display session 2
Resources:
Abstract
1228 - DACH1 induced stemness of intestinal organoids by directly suppressing BMP signaling and contributes to intestinal tumorigenesis
Presenter: Xiang Hu
Session: Poster Display session 2
Resources:
Abstract
1147 - miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions
Presenter: Hsiang-lin Tsai
Session: Poster Display session 2
Resources:
Abstract
1158 - Long noncoding RNA CASC21 promotes cell proliferation and metastasis in colon cancer.
Presenter: Qun Zhang
Session: Poster Display session 2
Resources:
Abstract
1259 - Prognostic and Predictive Impact On FMS-like Tyrosine Kinase 3 (FLT3) Amplification In Patients With Metastatic Colorectal Cancer
Presenter: Hiroko Hasegawa
Session: Poster Display session 2
Resources:
Abstract
1452 - RBP-Jκ in colon cancer cells facilitates tumor associated macrophages (TAMs)-induced cell metastasis by secreting CXCL11
Presenter: Meng jie Liu
Session: Poster Display session 2
Resources:
Abstract